human insulin

Details

Files

Generic Name:

human insulin

Project Status:

Complete

Therapeutic Area:

Diabetes mellitus

Manufacturer:

Eli Lilly Canada Inc.

Brand Name:

Entuzity KwikPen

Project Line:

Reimbursement Review

Project Number:

SR0672-000

NOC Status at Filing:

Post NOC

Biosimilar:

Manufacturer Requested Reimbursement Criteria¹:

To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

Submission Type:

Initial

Fee Schedule:

Schedule C

Indications:

To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day.

Date NOC Issued:

July 27, 2017

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

August 23, 2021

The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones
Call for patient/clinician input open	December 22, 2020
Call for patient/clinician input closed	February 22, 2021
Clarification: - Patient input submission received from Diabetes Canada
Submission received	January 27, 2021
Submission accepted	February 10, 2021
Review initiated	February 11, 2021
Draft CADTH review report(s) provided to sponsor for comment	April 30, 2021
Deadline for sponsors comments	May 11, 2021
CADTH responses on draft review report(s) provided to sponsor	June 04, 2021
Expert committee meeting (initial)	June 16, 2021
Draft recommendation issued to sponsor	June 29, 2021
Draft recommendation posted for stakeholder feedback	July 08, 2021
End of feedback period	July 22, 2021
Final recommendation issued to sponsor and drug plans	August 05, 2021
Final recommendation posted	August 23, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	August 19, 2021
CADTH review report(s) posted	October 06, 2021